Interestingly, dasatinib robustly inhibited SRC activity and its major target p-SRC in our HNSCC models; however, dasatinib did not alter the expression of various autophagy-related proteins or TSPAN1 (Figure S4B). This evidence concerns the gene SRC and head and neck squamous cell carcinoma.